OKYO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
OKYO Pharma Ltd is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has positive catalysts such as FDA Fast Track designation and promising Phase 2a trial results for urcosimod, the technical indicators are bearish, and there is no immediate trading signal from Intellectia Proprietary Trading Signals. The stock's pre-market price of $1.7 is below key support levels, indicating potential downside risk. Additionally, there is no valuation or financial performance data to assess the company's growth trends. It is advisable to monitor the stock for further developments before making a long-term investment decision.
The MACD histogram is -0.0163, below 0, and negatively contracting, indicating a bearish trend. The RSI is at 38.804, in the neutral zone, showing no clear signal. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The pre-market price of $1.7 is below the pivot level of 1.839, with key support at 1.568 and resistance at 2.11.
FDA Fast Track designation for urcosimod, significant pain reduction shown in Phase 2a trial, and plans for a multicenter Phase 2b/3 trial with 150 patients. High unmet need in neuropathic corneal pain market with no approved treatments.
Bearish technical indicators, lack of financial performance data, and no recent trading activity from hedge funds, insiders, or congress members.
No financial performance data available for analysis.
Analysts are optimistic with an Overweight rating from Piper Sandler and a Buy rating from B. Riley. Price targets are $7 and $5, respectively, reflecting significant upside potential. Analysts are encouraged by urcosimod's efficacy and safety profile and the high unmet need in the target market.
